May 5, 2020 / 10:42 AM / a month ago

Regeneron quarterly profit jumps 35% on higher demand for eye drug Eylea

May 5 (Reuters) - Regeneron Pharmaceuticals Inc on Tuesday reported a 35.4% rise in first-quarter profit on higher sales of its blockbuster eye drug, Eylea.

Net income rose to $624.6 million, or $5.43 per share, in the quarter ended March 31, from $461.1 million, or $3.99 per share, a year earlier.

Revenue rose to $1.83 billion from $1.37 billion. (Reporting By Saumya Sibi Joseph and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below